Skip to main content
. 2022 Jan 15;3(1):121–128. doi: 10.1002/jha2.359

FIGURE 2.

FIGURE 2

Progression‐free survival (PFS) of the entire cohort of patients from daratumumab starting therapy stratified according to scheme of therapy. Patients (pts) treated with DRd showed a better median PFS compared to pts treated with DVd (p = .007)